商務部:支持符合條件生科企業通過創業板、科創板及北交所上市
國家商務部、江蘇省人民政府發布《中國(江蘇)自由貿易試驗區生物醫藥全產業鏈開放創新發展方案》,力爭到2030年,江蘇自貿試驗區生物醫藥產業規模快速增長,創新生態持續優化,產業鏈現代化水平明顯提升,對外開放水平大幅提高,安全保障能力不斷增強,關鍵技術取得突破,在大分子生物藥、細胞和基因治療、創新醫療器械等重點領域培育形成具有特色優勢的產業集群。
發展方案將強化對產業發展的金融支持。支持符合條件的生物醫藥創新型企業通過在創業板、科創板及北交所上市,在新三板掛牌,以及發行公司信用類債券進行融資。鼓勵引導產業投資基金及創業投資基金等發起成立生物醫藥產業投資子基金。支持符合條件的生物醫藥產業園項目發行基礎設施領域不動產投資信託基金(REITs)及不動產信託資產支持票據。
方案指出,開展生物醫藥和醫療器械技術創新。支持佈局實施一批生物醫藥領域國家科技重大項目,加強大數據、人工智能在藥物靶標篩選、藥物分子設計及醫療器械設計製造等方面的應用。同時,加快建設生物醫藥及高端醫療器械先進製造業集群。在保證產品質量和充分評估風險的前提下,探索開展化學原料藥、生物製品分段生產試點,並探索開展人工智能醫學影像輔助診斷技術購買服務試點。
方案又提到,要提升臨床研究水平。支持江蘇自貿試驗區符合條件的醫療機構建設國家臨床醫學研究中心。支持具備條件的公立醫療機構增加臨床研究資源,組織開展多中心、大樣本臨床研究,探索開展去中心化臨床試驗試點,參與臨床研究國際標準和通用規範制定。支持開展真實世界研究,試點設立涉及人的區域生物醫學研究倫理審查委員會,推動醫療機構倫理審查結果互認。(ta/w) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.